These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29781558)

  • 41. A classifier based on 273 urinary peptides predicts early renal damage in primary hypertension.
    Lin L; Wang C; Ren J; Mei M; Zheng L; Yang J
    J Hypertens; 2023 Aug; 41(8):1306-1312. PubMed ID: 37199562
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria.
    Gaede P; Tarnow L; Vedel P; Parving HH; Pedersen O
    Nephrol Dial Transplant; 2004 Nov; 19(11):2784-8. PubMed ID: 15328385
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
    Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
    Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structural Predictors of Loss of Renal Function in American Indians with Type 2 Diabetes.
    Fufaa GD; Weil EJ; Lemley KV; Knowler WC; Brosius FC; Yee B; Mauer M; Nelson RG
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):254-61. PubMed ID: 26792530
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of urinary soluble E-cadherin as a novel biomarker for diabetic nephropathy.
    Jiang H; Guan G; Zhang R; Liu G; Cheng J; Hou X; Cui Y
    Diabetes Metab Res Rev; 2009 Mar; 25(3):232-41. PubMed ID: 19177462
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy.
    Lambers Heerspink HJ; Fowler MJ; Volgi J; Reutens AT; Klein I; Herskovits TA; Packham DK; Fraser IR; Schwartz SL; Abaterusso C; Lewis J;
    Diabet Med; 2007 Nov; 24(11):1290-5. PubMed ID: 17956455
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).
    Rutter MK; Prais HR; Charlton-Menys V; Gittins M; Roberts C; Davies RR; Moorhouse A; Jinadev P; France M; Wiles PG; Gibson JM; Dean J; Kalra PA; Cruickshank JK; Durrington PN
    Diabet Med; 2011 Jan; 28(1):100-8. PubMed ID: 21166851
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.
    Yamanouchi M; Skupien J; Niewczas MA; Smiles AM; Doria A; Stanton RC; Galecki AT; Duffin KL; Pullen N; Breyer MD; Bonventre JV; Warram JH; Krolewski AS
    Kidney Int; 2017 Jul; 92(1):258-266. PubMed ID: 28396115
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis.
    Meier M; Kaiser T; Herrmann A; Knueppel S; Hillmann M; Koester P; Danne T; Haller H; Fliser D; Mischak H
    J Diabetes Complications; 2005; 19(4):223-32. PubMed ID: 15993357
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Urinary afamin levels are associated with the progression of diabetic nephropathy.
    Kaburagi Y; Takahashi E; Kajio H; Yamashita S; Yamamoto-Honda R; Shiga T; Okumura A; Goto A; Fukazawa Y; Seki N; Tobe K; Matsumoto M; Noda M; Unoki-Kubota H
    Diabetes Res Clin Pract; 2019 Jan; 147():37-46. PubMed ID: 29522788
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy.
    van der Sande NG; Dorresteijn JA; Visseren FL; Dwyer JP; Blankestijn PJ; van der Graaf Y; Heerspink HL
    Diabetes Obes Metab; 2016 Nov; 18(11):1120-1127. PubMed ID: 27337598
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Urinary neutrophil gelatinase-associated lipocalin in type 2 diabetes: Relation to nephropathy and retinopathy.
    Hosny SS; Bekhet MM; Hebah HA; Mohamed NR
    Diabetes Metab Syndr; 2018 Nov; 12(6):1019-1024. PubMed ID: 29960862
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
    Katavetin P; Eiam-Ong S; Suwanwalaikorn S
    J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis.
    Takahashi S; Katada J; Daida H; Kitamura F; Yokoyama K
    J Hum Hypertens; 2016 Sep; 30(9):534-42. PubMed ID: 26674759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is Urinary NGAL Determination Useful for Monitoring Kidney Function and Assessment of Cardiovascular Disease? A 12-Month Observation of Patients with Type 2 Diabetes.
    Żyłka A; Gala-Błądzińska A; Dumnicka P; Ceranowicz P; Kuźniewski M; Gil K; Olszanecki R; Kuśnierz-Cabala B
    Dis Markers; 2016; 2016():8489543. PubMed ID: 28050059
    [No Abstract]   [Full Text] [Related]  

  • 57. Finerenone in chronic kidney disease and type 2 diabetes: the known and the unknown.
    Fu EL; Kutz A; Desai RJ
    Kidney Int; 2023 Jan; 103(1):30-33. PubMed ID: 36603981
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CKD273, a new proteomics classifier assessing CKD and its prognosis.
    Argilés Á; Siwy J; Duranton F; Gayrard N; Dakna M; Lundin U; Osaba L; Delles C; Mourad G; Weinberger KM; Mischak H
    PLoS One; 2013; 8(5):e62837. PubMed ID: 23690958
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Urinary proteins detected using modern proteomics intervene in early type 2 diabetic kidney disease - a pilot study.
    Golea-Secara A; Munteanu C; Sarbu M; Cretu OM; Velciov S; Vlad A; Bob F; Gadalean F; Gluhovschi C; Milas O; Simulescu A; Mogos-Stefan M; Patruica M; Petrica L; Zamfir AD
    Biomark Med; 2020 Nov; 14(16):1521-1536. PubMed ID: 33090017
    [No Abstract]   [Full Text] [Related]  

  • 60. Advice and challenges in the pharmacotherapeutic management of diabetic kidney disease in adults.
    Plattner C; Pirklbauer M; Mayer G
    Expert Opin Pharmacother; 2023; 24(16):1747-1752. PubMed ID: 37599563
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.